Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

Reuters Pharma 2025

AI and away we go: key insights from Reuters Pharma 2025

AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications across marketing, drug discovery, and patient engagement, despite challenges in adoption, regulation, and data trust.

Cuttsy + Cuttsy

- PMLiVE

Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

- PMLiVE

Roche to boost US footprint with $50bn investment over next five years

The commitment is aimed at bolstering the company’s pharmaceutical and diagnostics divisions

- PMLiVE

Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial

As many as half of patients with high-risk NMIBC experience disease recurrence despite BCG treatment

- PMLiVE

Health misinformation: can pharma really have an impact?

False health narratives can erode trust, endanger lives and undermine medical progress

- PMLiVE

Why Generic Pharma Companies Need a Comms Partner That Thinks & Works Like They Do

Generics account for 81% of U.K. primary care prescriptions but just 28% of NHS medicines spending, delivering significant value under growing financial pressures. However, persistent pricing challenges and supply chain...

Fox&Cat

- PMLiVE

Medscape Education: Proud Friend of COA Sponsor at the Community Oncology Conference

Medscape Education is honored to be a Friend of COA sponsor at the Community Oncology Conference, taking place from April 28-30th in Orlando, FL. This partnership highlights our commitment to...

Medscape Education

- PMLiVE

Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

More than 2.5 million people in Europe are living with the inflammatory bowel disease

- PMLiVE

Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m

The companies will focus on developing treatments for hard-to-treat ALT-positive tumours

- PMLiVE

Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease

- PMLiVE

The AI revolution in healthcare – unlocking a new era of medical innovation

Ensuring AI tools comply with strict standards while promoting fairness, accountability and reliability

- PMLiVE

Roche’s Genentech enters $765m autoimmune disease partnership with Repertoire

The collaboration will leverage Repertoire’s immune mapping DECODE platform

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links